Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy

Oncologist

Volumn 16, Issue 2, 2011, Pages 228-238

  Pinto, Carmine ^a   Barone, Carlo Antonio ^b   Girolomoni, Giampiero ^c   Ussi, Elvio Grazioso ^d   Merlano, Marco Carlo ^e   Ferrari, Daris ^f   Maiello, Evaristo ^g  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Radiotherapy Unit   (Italy)

^e S CROCE E CARLE HOSPITAL   (Italy)

^f SAN PAOLO HOSPITAL   (Italy)

^g CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Cetuximab; EGFR; Italian expert opinions; Skin rash; Skin toxicity

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CETUXIMAB; CLINDAMYCIN; CORTICOSTEROID; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN; ISOTRETINOIN; METHYLPREDNISOLONE; METRONIDAZOLE; MINOCYCLINE; PREDNISONE;

ARTICLE; BURN DRESSING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONSENSUS DEVELOPMENT; DEBRIDEMENT; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; HAIR DISEASE; HEAD AND NECK CARCINOMA; HUMAN; ITALY; MEDICAL LITERATURE; MEDLINE; MUCOSA INFLAMMATION; NAIL DISEASE; OUTCOME ASSESSMENT; PARONYCHIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; PUSTULE; QUALITY OF LIFE; RADIATION DERMATITIS; SCORING SYSTEM; SKIN EXAMINATION; SKIN TOXICITY; SUPERINFECTION; SYSTEMATIC REVIEW; WOUND DRESSING;

ADMINISTRATION, CUTANEOUS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ERUPTIONS; EXANTHEMA; HEAD AND NECK NEOPLASMS; HUMANS; MUCOSITIS; PARONYCHIA; PRURITUS; QUALITY OF LIFE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79952601240     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0298     Document Type: Article

References (68)

1. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-3035.
2. Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
3. Zambruno G, Girolomoni G, Manca V et al. Epidermal growth factor and transferrin receptor expression in human embryonic and fetal epidermal cells. Arch Dermatol Res 1990;282:544-548.
4. Pastore S, Mascia F, Mariani V et al. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 2008;128:1365-1374.
5. van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
6. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
7. van Cutsem E, Lang I, Folprecht G et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. Paper presented at: Proc 2010 Gastrointestinal Cancers Symposium; January 22-24; Orlando, Florida; abstract 281.
8. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
9. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048.
10. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. NEngl J Med 2008;359: 1757-1765.
11. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
12. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
13. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-28.
14. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
15. Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
16. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.
17. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5557.
18. Lenz HJ, Van Cutsem E, Khambata-Ford S et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921.
19. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an astern Cooperative Oncology Group Study. J Clin Oncol 2005;23:8646-8654.
20. Berlin J, Van Cutsem E, Peeters M et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): a pooled analysis of five clinical trials. J Clin Oncol 2007;25:abstract 4134.
21. Baselga J, Pfister D, Cooper MR et al. Phase I study of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-914.
22. Tejpar S, Peeters M, Humblet Y et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): the EVEREST experience (preliminary data). J Clin Oncol 2008;26:abstract 4001.
23. Lièvre A, Bacher J-B, Boige V et al. K-ras mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
24. Peeters M, Siena S, Van Cutsem E et al. Association of progression-free survival, overall survival, and patients-reported outcomes by skin toxicity and Kras status in patients receiving panitumumab monotherapy. Cancer 2009;115:1544-1554.
25. Orditura M, De Vita F, Galizia G et al. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis. Oncol Rep 2009;21:1023-1028.
26. Vermorken JB, Trigo J, Hitt R et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-2177.
27. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
28. Duffour J, Thézenas S, Dereure O et al. Interobserver agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study. Eur J Cancer 2010; Published April 21, 2010;doi: 10.1016/j.ejca. 2010.03.008.
29. Brook RH, Gompert DC. The RAND/UCLA Appropriateness Method, "Clinical practice guideline development: methodology perspectives. Rockville (MD): Public Health Service, AHCR, 1994.
30. Bernier J, Bonner J, Vermorken JB et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19:142-149.
31. Giro C, Berger B, Bolke E et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother Oncol 2009;90:166-171.
32. Pryor DI, Porceddu SV, Burmeister BH et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009;90:172-176.
33. Russi EG, Merlano MC, Comino A et al. Ultra thin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. Alte RCC Italian Trial). Int J Radiat Oncol Biol Phys 2007;69:638-639.
34. Skvortsova I. Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiother Oncol 2009;90:281-282.
35. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119.
36. Osio A, Mateus C, Soria JC et al. Cutaneous side-effects in patients on longterm treatment with epidermal growth factor receptor inhibitors. Br J Dermatol 2009;161:515-521.
37. Su X, Lacouture ME, Jia Y et al. Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 2009;77:124-133.
38. Melosky B, Burkes R, Rayson D et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16-26.
39. Racca P, Fanchini L, Caliendo V et al. Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation. Clin Colorectal Cancer 2008;7:48-54.
40. Segaert S, Tabernero J, Chosidow O et al. The management of skin reaction in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606.
41. Scope A, Liza A, Agero C et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-5396.
42. Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème. Radiol Oncol 2008;42:215-224.
43. Jatoi A, Green EM, Rowland KM et al. Clinical predictors of severe cetuximab- induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009;77:120-123.
44. Agero AL, Dusza SW, Andrade CB et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitor. J Am Acad Dermatol 2006;55:657-670.
45. Hu JC, Sadeghi P, Pinter-Brown LC et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-326.
46. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-1176.
47. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-3462.
48. Schwartz G, Dutcher JP, Vogelzang NJ et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol 2002;21:abstract 91.
49. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
50. Herbst RS, LoRusso PM, Purdom M et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003;4:366-369.
51. Kimyai-Asadi A, Jih MH. Follicular toxic effects of chimeric antiepidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002;138:129-131.
52. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in nonsmall cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-26.
53. Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with nonesmall-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
54. Fox LP. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 2007;56:460-465.
55. Lai SE, Minnelly L, O'Keeffe P et al. Influence of skin color in the development of erlotinib-induced rash: a report from the SERIES clinic. J Clin Oncol 2007;25:abstract 9127.
56. National Cancer Institute. Common terminology criteria for adverse event v. 2.0 1999, v. 3.0 2006, v. 4.0 2009; http://ctep.cancer.gov/reporting/ctc.html.
57. Wollenberg A, Moosmann N, Klein E et al. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008;17: 790-792.
58. Lacouture ME, Maithand ML, Saegart S et al. A propsed EGFR inhibitor adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010;18:509-522.
59. Romito F, Giuliani F, Cormio C et al. Psychological effects of cetuximabinduced cutaneous rash in advanced colorectal cancer patients. Support Care Cancer 2010;18:329-334.
60. Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010;116:3916-3923.
61. Eriksen JG, Overgaard M. Late onset of skin toxicity induced by EG Frinhibitors. Radiother Oncol 2009;90:280-281.
62. Merlano MC, Russi EG. Epidermal Growth factor receptor-inhibitors and radiotherapy-induced cutaneous adverse effects: "Koebner-Phenomenon" or radio-dermatitis? Radiother Oncol 2009;92:142-143.
63. Mak SS, Lolassiotis A, Wan W et al. The effects of hydrocolloid dressing and gentian violet on radiation-induced moist desquamation wound healing. Cancer Nurs 2000;23:220-229.
64. Bone RC. Systemic inflammatory response syndrome: a unifying concept of systemic inflammation. In: Fein A, Abraham A et al., eds. Sepsis and Multi organ Failure. Philadelphia, Pa: Lippincott, Williams, & Wilkins, 1997:1-10.
65. Boone SL, Rademaker A, Liu D et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152-159.
66. Ocvirk J, Rebersek M. Topical application of vitamin K1 cream for cetuximab- related skin toxicities. Ann Oncol 2009; 20(suppl 7):vii22-vii23. Paper presented at: ESMO Conference: 11th World Congress on Gastrointestinal Cancer; June 24-27, 2009; Barcelona, Spain; abstract PD-0021.
67. Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical application of vitamin K1 cream. J Clin Oncol 2009; 27(suppl 20):e15087. Paper presented at: 45th ASCO Annual Meeting; May 2009; Orlando, Florida; abstract e15087.
68. Radovics N, Kornek G, Thalhammer F et al. Analysis of the effects of vitamin K1 cream on cetuximab-induced acne-like rash. J Clin Oncol 2010; 28(suppl):e19671. Paper presented at: 46th ASCO Annual Meeting; June 4-8, 2010; Chicago, Illinois; abstract e19671.